Although conventional surgical resection, chemoradiotherapy combined with immunotherapy and electric field therapy improve the prognosis of glioma patients to an extent, the overall prognosis of glioma patients remains poor due to the glioma heterogeneity and epigenetic mutations of intratumoral molecules (including isocitric dehydrogenase (IDH) and epidermal growth factor receptor mutations, 1p19q co-deletion, and MGMT promoter methylation). This evidence concerns the gene MGMT and central nervous system cancer.